TEL AVIV, Israel, June 26, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q2 2025 Aide Memoire is available on the “Investors” page ...

Teva Pharmaceutical (NYSE: TEVA) and Shanghai Fosun Pharmaceutical (OTCPK:SFOSF) announced a collaboration on Monday to develop TEV-56278, a new therapy aimed at treating various cancers through ...

Teva outlines its accelerated growth strategy focused on innovation, aiming for $5 billion in biopharma revenue by 2030, while maintaining a strong generics and biosimilars base.

Teva Pharmaceuticals continues to beat consensus estimates, has once again raised its 2025 financial guidance and secured credit upgrades. Read more on why TEVA stock is a Buy.

We came across a bullish thesis on Teva Pharmaceutical Industries Limited (TEVA) on Substack by Kontra. In this article, we will summarize the bulls’ thesis on TEVA. Teva Pharmaceutical ...

The Teva Zymic Sandals are 50% off right now at Nordstrom Rack. Shoppers say they feel like “walking on marshmallows” that are “bathed in comfort.” ...

Teva Pharmaceutical Industries and partner Alvotech said the Food and Drug Administration agreed to review their AVTO6 treatment for eye disorders, which could compete with Regeneron ...

We came across a bullish thesis on Teva Pharmaceutical Industries Limited (TEVA) on Substack by Kontra. In this article, we will summarize the bulls’ thesis on TEVA.

Amid a reorganization campaign that’s breathed new life into hybrid generic and innovative medicines player Teva, the company is leaning into novel medicines and formulations more than ever and ...

Teva Pharmaceuticals will pay $450 million to resolve allegations of kickback schemes involving Medicare copays and price-fixing. This settlement is part of a broader crackdown on healthcare fraud ...